tirzepatide news 2025 New clinical trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss FDA's Removal of Semaglutide and

In a study by Drucker et al

If left untreated, hyperthyroidism can lead to major issues such as heart disease, bone loss, and, in severe circumstances, a life-threatening thyroid storm

A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week

Reduced potency from expired medication may mean your glucose levels are higher than expected

The peptide's predictable dose-response and extended stability in culture media have made it a preferred growth factor supplement in CHO cell culture, stem cell expansion, and primary cell isolation protocols across hundreds of published studies

Eligible patients may discuss FDA-approved Zepbound, compounded tirzepatide programs, insurance verification, and self-pay treatment options based on clinical needs and provider recommendations